UCB has chosen Daiichi Sankyo as its new commercial partner in Japan for an epilepsy drug, building on an existing relationship in the allergy area.

Glenmark, Ranbaxy Laboratories, Sun Pharma and other India drug makers are among 15 sued in a U.S. federal court for violating the patent of the epilepsy drug Vimpat (lacosamide) licensed to UCB.

Pfizer Inc.'s acquisition of worldwide rights to Schwarz's registration-stage incontinence product fesoterodine for $210 million plus royalties is the most recent milestone in the German company's successful integration of drug development to its legacy marketing organization-and one that nearly guarantees it a substantial revenue stream regardless of how fesoterodine fares in the marketplace.